SNDX
Syndax Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.50
−0.88%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.8x
Market Cap
$1.83B
MomentumView details →
1D Return
−0.88%
YTD Return
−1.29%
RSI (14)
55.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.8x
Market Cap
$1.83B
RSI (14)
55.1
MomentumView details →
1D Return
−0.88%
YTD Return
−1.29%
SummaryUpdated Jun 1, 2026
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Waltham, Massachusetts. The company went public in March 2016 and has evolved from a research-focused organization into a commercial-stage company with two FDA-approved products launched in 2024. Syndax specializes in developing novel therapies for cancer treatment, with particular expertise in targeting specific protein interactions and immune system pathways that drive tumor growth and resistance to treatment.
Similar companies
Latest newsMore news →
Syndax Pharmaceuticals reported second quarter 2026 financial results, with total revenue of $73 million, a 92% year-over-year increase.31d agoSyndax Pharmaceuticals issued $250.0 million of 2.25% Convertible Senior Notes due 2031, with net proceeds of approximately $243.0 million for general corporate purposes.87d ago